Asset profile
Ziltivekimab
Monoclonal antibody
Evidence outlook · lead readout
ZEUS (NCT05021835) · Cardiovascular Risk, Chronic Kidney Disease, Inflammation
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
ZEUS (NCT05021835): The study is a large randomized, quadruple-blind, placebo-controlled trial with 6,385 participants and a hard clinical primary endpoint measuring cardiovascular death, non-fatal heart attack, or non-fatal stroke. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Atherosclerotic Cardiovascular Disease · Phase 3Heart Failure · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
162 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 162 same-indication; 50 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ziltivekimab: this drug | Phase 3 | Monoclonal antibody | Interleukin-6 | ||
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Bempedoic Acid (Nexletol) | Approved | Small molecule | Adenosine Triphosphate-Citrate Lyase Inhibitor, ATP citrate lyase | ||
| Bempedoic Acid / Ezetimibe | Approved | Small molecule | ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Cangrelor (Kengreal) | Approved | Small molecule | P2Y12 receptor | ||
| Colchicine (cardiovascular) (Lodoco) | Approved | Small molecule | Microtubule/inflammasome (tubulin) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 |
…and 147 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
January 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.